BRAF and melanoma: In the present study, we investigate the impact of V600EBRAF mutation on melanoma cell senescence (β-Gal activity and cyclin D1, pRB, p53 and p21 expression) in a panel of mutant BRAF melanoma cell lines including vemurafenib-sensitive cells as well as cells with intrinsic or acquired resistance to the drug in vitro and in vivo.